The Abiomed Impella Heart Pump Recalls: What Patients and Families Need to Know

The Impella, made by Abiomed, is a percutaneous ventricular assist device. Instead of open surgery, a doctor threads it through a catheter, usually from an artery in the groin, up into the left ventricle. Once in place, the pump pulls blood out of the ventricle and pushes it into the aorta, taking over part of the work a weakened heart cannot do on its own. It is temporary support, used for hours or days, not a permanent implant.

Cardiologists reach for the Impella in some of the highest-stakes moments in medicine: high-risk procedures to open blocked coronary arteries, heart attacks, and cardiogenic shock, the state where a damaged heart can no longer pump enough blood to keep the body alive. The FDA has cleared versions of the pump for those uses. When it works, it buys the heart time to recover.

It helps to keep the Impella separate from the other heart pump this firm has written about. Our article on the Medtronic HVAD recall covers a different device, the HeartWare HVAD, which surgeons implanted for long-term support in advanced heart failure. The HVAD was pulled from the market in 2021. The Impella is still sold and still used. Both are forms of mechanical circulatory support, and both carry recall histories that patients and families have a right to understand.

Abiomed is no longer an independent company. Johnson & Johnson announced a deal to acquire it in November 2022 for roughly 16.6 billion dollars, and Abiomed now operates within Johnson & Johnson MedTech. The recalls described below span that change in ownership.

In December 2023, Abiomed sent hospitals an Urgent Medical Device Correction. In March 2024 the FDA classified the action as a Class I recall, the agency's most serious category, reserved for problems it believes can cause serious injury or death.

The reason, in the FDA's own words, was that the pump catheter may perforate, meaning cut, the wall of the left ventricle. A perforation of the heart wall can lead to bleeding around the heart, loss of blood flow, and death. The FDA said the risk was higher in certain patients, including people with an anterior heart attack, elderly patients, and women.

The numbers are the part families remember. The FDA reported 129 serious injuries, including 49 deaths, connected to the problem. The recall covered 66,390 devices distributed in the United States between October 10, 2021 and October 10, 2023, across the Impella product line: the Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella 5.5 with SmartAssist, and Impella LD.

One detail matters for anyone trying to make sense of this. The 2024 recall was a correction, not a removal. Abiomed did not pull the pumps off the shelf. It updated the instructions for use, and hospitals kept using the devices with the revised guidance. That is legal and common, but it means the same pumps that were tied to those injuries stayed in service. A recall in this form is a warning about how a product is used, not proof the product is gone.

The 2024 recall was not the end of the story. In 2026 the FDA classified a series of new Class I actions touching nearly every part of the Impella system: the pumps, the controllers that run them, and the introducer sheaths used to put them in.

The most recent centers on the introducer, the sheath a doctor uses to gain access to the artery. Abiomed and its manufacturing partner Oscor identified a potential for the sheath to leak in the 14 French and 23 French sizes, from the sidearm, from under the sheath cap, and along score lines in the hub. The FDA warned that the leakage can cause access-site bleeding that needs medical intervention and, in certain circumstances, life-threatening hemorrhage and instability in a patient's circulation that may lead to death. Abiomed and Oscor sent affected customers a letter dated June 10, 2026, and the FDA classified the recall as Class I later that summer. Federal records list more than a dozen separate recall entries tied to the single event, numbered Z-2681-2026 through Z-2693-2026.

On the question of harm, the record is more measured than the 2024 figures, and the company's position deserves to be stated plainly. As of April 22, Abiomed reported eight instances of major bleeding and three complaints with corresponding patient deaths. The company said it determined that those deaths were not attributable to the leakage itself. That is Abiomed's assessment, and whether it holds up is exactly the kind of question a records review exists to test.

Separately, in June 2026 the FDA classified Class I recalls on the Automated Impella Controller, the bedside unit that drives the pump. According to the agency and reporting from the American Hospital Association, the actions covered an internal software error that could occur when a patient went more than 80 minutes with no residual pulse, along with low purge pressure alarms, a risk of clot formation during prolonged use, and a retrospective review that flagged alarm failures, power-path faults, and electrical-short risks. Like the 2024 recall, these were framed as corrections and updates rather than removals from clinical use.

None of that is our characterization. Those are the manufacturer's disclosures and the FDA's classifications, drawn from the agency's recall database. What they add up to is a device family that has drawn the government's highest safety alert repeatedly, across the pump, its controller, and its access hardware, in a short span of time.

A recall does not pay anyone. It is a manufacturer's acknowledgment, sometimes a reluctant one, that a product carries a risk. The legal claim comes later, when a patient or family can show that the device failed, or was used improperly, and caused harm that otherwise would not have happened.

The Impella is used in desperately sick patients, and that is the honest complication in these cases. A person in cardiogenic shock may die from the underlying heart condition no matter what the pump does. That does not end the inquiry. It sharpens it. The question a case turns on is whether a specific harm traces to the device or its use rather than to the illness that brought the patient to the catheterization lab.

The patterns worth looking for in a medical record: a perforation of the heart wall or bleeding around the heart during or shortly after Impella placement; uncontrolled bleeding at the access site in the groin; a stroke, cardiac arrest, or death that followed a controller alarm, a pump interruption, or a purge problem; and evidence of clotting tied to the device. If one of those appears in your family's timeline, the connection to the pump may never have been explained to you. That is common, and it is what a case review is for.

Claims involving the Impella can run on two tracks. A product liability claim targets the manufacturer on theories of design defect, manufacturing defect, or failure to warn. The 2024 perforation recall and the 2026 introducer leakage recall both describe the kinds of problems those theories are built to address, though a recall is a starting point for investigation, not a finished verdict against anyone.

A medical malpractice claim targets the doctor or hospital. In an Impella case that might involve improper placement of the catheter, failure to recognize a perforation, failure to respond to controller alarms, or inadequate monitoring of a patient on mechanical support. The two tracks can overlap in a single case, and which theory fits depends on the facts in the records. Our article on choosing a medical malpractice attorney explains why matching the theory to the proof matters as much as the strength of the sympathy in a case.

These cases generally proceed individually, each on its own facts and its own medical record, rather than through a single consolidated proceeding. That makes documentation decisive: the medical records, the device and controller data, and the recall timeline have to be read together. It is the same lesson from the HVAD cases, where the story lived in three places at once.

One path matters for veterans and military families. If the procedure happened at a VA medical center or another federal facility, a claim about the medical care proceeds under the Federal Tort Claims Act, with its own strict administrative deadline, while any product claim against the manufacturer proceeds separately. Our FTCA article walks through how those government cases work and why the two tracks can run at the same time.

The deadlines are unforgiving, and they are already running. Virginia generally allows two years from the date of injury or death for personal injury, wrongful death, and product liability claims. The District of Columbia generally allows three years, and Maryland generally allows three years with an outer cap. A claim tied to care at a federal facility runs under the FTCA's two-year administrative clock, which starts before any lawsuit is filed. These are general rules, and the exact deadline for a specific case depends on facts an attorney has to check.

The discovery rule can change when the clock starts if the link between the device and the harm was not reasonably apparent at the time. In Impella cases that link is often invisible to a family. A death in a cardiac ICU gets attributed to the heart attack, and no one mentions a heart pump recall the family never heard about. Whether the discovery rule rescues a particular claim is a case-specific question that should be answered by a lawyer, not assumed in either direction.

The practical advice is simple. Waiting is the expensive mistake. Evidence gets harder to gather, memories fade, and deadlines pass while a family assumes nothing can be done. The clock is already running, and the only way to learn where you stand is to ask now, while the answer can still help. A case review costs nothing, and the deadline question is usually the first thing we work out.

National Malpractice Lawyers represents patients and families in claims involving defective medical devices and the medical negligence that can accompany their use. This is our Defective Medical Devices practice area, the same one that covers our Medtronic HVAD and Mazor X surgical robot coverage. In device cases the truth usually sits in three records at once: the medical chart, the device and controller data, and the recall timeline. We read them together.

If you or a family member had an Impella heart pump placed and suffered a perforation, uncontrolled bleeding, a stroke, or death that may connect to the device, contact us for a confidential case review. Peter Anderson reads these inquiries personally. There is no fee unless we recover for you.